New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
Life Sciences Conference is being held in New York on April 8-9.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 27, 2015
09:34 EDTISISIsis Pharmaceuticals reports Q4 EPS 25c, consensus 2c
Subscribe for More Information
09:06 EDTACADACADIA price target raised to $50 from $31 at JMP Securities
JMP Securities increased its price target on ACADIA based on its higher sales estimates for the company's anti-psychotic drug, NUPLAZID, after the company raised the price of the drug. The firm reiterates an Outperform rating on the shares.
07:41 EDTBCRC.R. Bard has a conference call hosted by JPMorgan
Subscribe for More Information
February 26, 2015
18:43 EDTACADOn The Fly: After Hours Movers
Subscribe for More Information
16:14 EDTACADACADIA reports Q4 EPS (28c), consensus (26c)
Subscribe for More Information
15:30 EDTISISNotable companies reporting before tomorrow's open
Subscribe for More Information
February 24, 2015
16:47 EDTGNMKGenMark sees FY15 revenue $38M-$40M, consensus $39.39M
16:46 EDTGNMKGenMark reports Q4 EPS (21c), consensus (28c)
Subscribe for More Information
12:22 EDTACADOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:48 EDTISISIsis says ISIS-PKKRx reduced prekallikrein levels in Phase 1 study
Isis Pharmaceuticals announced results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95% in prekallikrein, or PKK, Isis said. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema. ISIS-PKKRx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg up to 400 mg for the multiple doses. After three weeks of dosing, subjects in the 100, 200, 300 and 400 mg multiple-dose cohorts displayed a mean reduction of PKK of 33, 69, 87 and 92%, respectively, from baseline. In this study, ISIS-PKKRx was generally well tolerated.
07:06 EDTACADACADIA initiated with a Buy at H.C. Wainwright
Subscribe for More Information
February 23, 2015
16:34 EDTLXRXLexicon Chief Scientific Officer resigns
Lexicon Pharmaceuticals announced the resignation of Brian Zambrowicz, Ph.D., executive vice president and Chief Scientific Officer, to pursue another opportunity. Dr. Zambrowicz will be assisting in shifting his responsibilities to other members of the company in order to ensure a seamless transition. In connection with the change, Lexicon will merge its discovery and clinical functions and conduct an immediate search for a head of research and development. Dr. Zambrowicz has agreed to be available to provide consulting services as the company completes this transition.
07:22 EDTISISSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 20, 2015
15:20 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information
February 19, 2015
11:56 EDTBCRC.R. Bard repoprts CMS approves pass-through payment for Lutonix DCB
Subscribe for More Information
February 18, 2015
16:55 EDTEXAMExamWorks sees Q1 constant currency revenue $198M-$204M, consensus $200.29M
Subscribe for More Information
16:54 EDTEXAMExamWorks sees FY15 constant currency revenue growth 8%-10%, consensus $844.25M
Subscribe for More Information
16:52 EDTEXAMExamWorks reports Q4 EPS (4c), consensus 1c
Reports Q4 revenue $202.1M, consensus $194.90M.
09:05 EDTSGENSeattle Genetics submits supplemental BLA to FDA for Phase 3 Aethera trial
Seattle Genetics announced that it has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration based on data from the phase 3 AETHERA trial of ADCETRIS as consolidation therapy immediately following an autologous stem cell transplant in Hodgkin lymphoma patients at high risk of relapse. ADCETRIS is an antibody-drug conjugate directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma. ADCETRIS is approved in relapsed HL and sALCL but is currently not approved for consolidation therapy in HL patients immediately after ASCT. The supplemental BLA is based on positive results from a phase 3 clinical trial called AETHERA that were presented at the 56th American Society of Hematology Annual Meeting in December 2014. Results from the AETHERA trial in 329 HL patients at high risk of relapse included: The trial achieved its primary endpoint and demonstrated a significant increase in progression-free survival per independent review facility, with a hazard ratio of 0.57 and a p-value of 0.001. Median PFS was 43 months for patients who received ADCETRIS versus 24 months for patients who received placebo. The two-year PFS rate was 63 percent in the ADCETRIS arm compared to 51 percent in the placebo arm. The PFS benefit was consistent across all pre-specified subgroups, including primary refractory patients, patients who relapsed within twelve months of frontline therapy and patients who relapsed after twelve months with extranodal disease.
06:12 EDTONCSHeat Biologics and OncoSec partner to combine immunotherapy platforms
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use